Efficacy of varenicline for smoking cessation

Comment

Alain Dervaux et al. JAMA. 2006.

. 2006 Dec 6;296(21):2555; author reply 2555-6.

doi: 10.1001/jama.296.21.2555-a.

No abstract available

Comment on

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group. Gonzales D, et al. JAMA. 2006 Jul 5;296(1):47-55. doi: 10.1001/jama.296.1.47. JAMA. 2006. PMID: 16820546 Clinical Trial.
Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group. Jorenby DE, et al. JAMA. 2006 Jul 5;296(1):56-63. doi: 10.1001/jama.296.1.56. JAMA. 2006. PMID: 16820547 Clinical Trial.
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group. Tonstad S, et al. JAMA. 2006 Jul 5;296(1):64-71. doi: 10.1001/jama.296.1.64. JAMA. 2006. PMID: 16820548 Clinical Trial.